1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Genomics and Human Genetics
  4. Volume 18, 2017
  5. Article

Annual Review of Genomics and Human Genetics

Volume 18, 2017

Precisely Where Are We Going? Charting the New Terrain of Precision Prevention

Abstract

In addition to genetic data, precision medicine research gathers information about three factors that modulate gene expression: lifestyles, environments, and communities. The relevant research tools—epidemiology, environmental assessment, and socioeconomic analysis—are those of public health sciences rather than molecular biology. Because these methods are designed to support inferences and interventions addressing population health, the aspirations of this research are expanding from individualized treatment toward precision prevention in public health. The purpose of this review is to explore the emerging goals and challenges of such a shift to help ensure that the genomics community and public policy makers understand the ethical issues at stake in embracing and pursuing precision prevention. Two emerging goals bear special attention in this regard: () public health risk reduction strategies, such as screening, and () the application of genomic variation studies to understand and reduce health disparities among population groups.

Keyword(s): ELSI, genomics, health disparities, precision medicine, prevention, public health
Loading

Article metrics loading...

/content/journals/10.1146/annurev-genom-091416-035222
2017-08-31
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/genom/18/1/annurev-genom-091416-035222.html?itemId=/content/journals/10.1146/annurev-genom-091416-035222&mimeType=html&fmt=ahah

Literature Cited

  1. Adams MC, Evans JP, Henderson GE, Berg JS. 1.  2016. The promise and peril of genomic screening in the general population. Genet. Med. 18:593–99 [Google Scholar]
  2. Almannai M, Marom R, Sutton VR. 2.  2016. Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing. Curr. Opin. Pediatr. 28:694–99 [Google Scholar]
  3. Andermann A, Blancquaert I, Beauchamp S, Déry V. 3.  2008. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull. World Health Organ. 86:317–19 [Google Scholar]
  4. Bayer R, Galea S. 4.  2015. Public health in the precision medicine era. N. Engl. J. Med. 373:499–501 [Google Scholar]
  5. Bibbins-Domingo K. 5.  2016. Opening remarks. Precision Public Health Summit: summit report: June 6–7, 20166 https://cvp.ucsf.edu/PPHS-Summit-Report-For-Posting.pdf
  6. Braveman PP, Gotlieb L. 6.  2014. The social determinants of health: It's time to consider the causes of the causes. Public Health Rep 129:Suppl. 219–31 [Google Scholar]
  7. Bravo P, Edwards A, Bar PJ, Scholl I, Elwyn G. 7.  et al. 2015. Conceptualising patient empowerment: a mixed methods study. BMC Health Serv. Res. 15:252 [Google Scholar]
  8. Browner CH. 8.  2011. Lost in translation: lessons from California on the implementation of state-mandated fetal diagnosis in the context of globalization. Reproduction, Globalization, and the State: New Theoretical and Ethnographic Perspectives CH Browner, CF Sargent 204–23 Durham, NC: Duke Univ. Press [Google Scholar]
  9. Burke W, Coughlin SS, Lee NC, Weed DL, Khoury MJ. 9.  2001. Application of population screening principles to genetic screening for adult-onset conditions. Genet. Test. 5:201–11 [Google Scholar]
  10. Burton H, Chowdhury S, Dent T, Hall A, Pashayan N. 10.  et al. 2013. Public health implications from COGS and potential for risk stratification and screening. Nat. Genet. 45:349–51 [Google Scholar]
  11. Carey DJ, Fetterolf SN, Davis FD, Faucett WA, Kirchner HL. 11.  et al. 2016. The Geisinger MyCode community health initiative: an electronic health record-linked biobank for precision medicine research. Genet. Med. 18:906–13 [Google Scholar]
  12. Chatterjee N, Shi J, García-Closas M. 12.  2016. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nature 17:392–406 [Google Scholar]
  13. Chetty R, Stepner M, Abraham S, Lin S, Scuderi B. 13.  et al. 2016. The association between income and life expectancy in the United States, 2001–2014. JAMA 315:1750–66 [Google Scholar]
  14. Clarke AE, Shim JK, Mamo L, Fosket JR, Fishman JR. 14.  2003. Biomedicalization: technoscientific transformations of health, illness, and U.S. biomedicine. Am. Sociol. Rev. 68:161–94 [Google Scholar]
  15. Cohn EG, Henderson GE, Appelbaum PS. 15.  2016. Distributive justice, diversity and inclusion in precision medicine: What will success look like?. Genet. Med. 19:157–59 [Google Scholar]
  16. Collins FS. 16.  2004. What we do and don't know about ‘race’, ‘ethnicity’, genetics and health at the dawn of the genome era. Nat. Genet. 36:S13–15 [Google Scholar]
  17. Cooper RS, Kaufman JS, Ward R. 17.  2003. Race and genomics. N. Engl. J. Med. 348:1166–70 [Google Scholar]
  18. Corbie-Smith G, Henderson GE, Blumenthal C, Dorrance J, Estroff S. 18.  2008. Conceptualizing race in research. J. Natl. Med. Assoc 1001235–43 [Google Scholar]
  19. de Vries J, Jallow M, Williams TN, Kwiatkowski D, Parker M. 19.  et al. 2012. Investigating the potential for ethnic group harm in collaborative genomics research in Africa: Is ethnic stigmatisation likely?. Soc. Sci. Med. 75:1400–7 [Google Scholar]
  20. Desmond-Hellmann S. 20.  2016. Opening remarks. Precision Public Health Summit: summit report: June 6–7, 20164 https://cvp.ucsf.edu/PPHS-Summit-Report-For-Posting.pdf
  21. Dewey FE, Murray MF, Overton JD, Habegger L. 21.  2016. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science 354:aaf6814 [Google Scholar]
  22. Dotson WD, Douglas MP, Kolor K, Stewart AC, Bowen MS. 22.  et al. 2014. Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin. Pharmacol. Ther. 95:394–402 [Google Scholar]
  23. Evans JP, Berg JS. 23.  2011. Next-generation DNA sequencing, regulation, and the limits of paternalism: the next challenge. JAMA 306:2376–77 [Google Scholar]
  24. Evans JP, Berg JS, Olshan AF, Magnuson T, Rimer BK. 24.  2013. We screen newborns, don't we? Realizing the promise of public health genomics. Genet. Med. 15:332–35 [Google Scholar]
  25. Fang J, Yang Q, Ayala C, Loustalot F. 25.  2014. Disparities in access to care among US adults with self-reported hypertension. Am. J. Hypertens. 27:1377–86 [Google Scholar]
  26. Feero WG, Guttmacher AE, Collins FS. 26.  2010. Genomic medicine: an updated primer. N. Engl. J. Med. 362:2001–11 [Google Scholar]
  27. Feinberg D, Steele G, Robeznieks A. 27.  2015. Aiming to provide concierge care ‘for the masses. .’ Mod. Healthc. 45:30–31 [Google Scholar]
  28. Finer BS. 28.  2016. The rhetoric of previving: blogging the breast cancer gene. Rhetoric Rev 35:176–88 [Google Scholar]
  29. Fishman JR, McGowan ML. 29.  2014. Will personal genomic information transform one's self?. Genetics as Social Practice: Transdisciplinary Views on Science and Culture B Prainsack, S Schicktanz, G Werner-Felmeyer 29–42 London: Ashgate [Google Scholar]
  30. Foster M, Sharp R. 30.  2004. Beyond race: towards a whole-genome perspective on human populations and genetic variation. Nat. Rev. Genet. 5:790–96 [Google Scholar]
  31. Fukunaga-Kalabis M, Herlyn M. 31.  2012. Cancer: complexion matters. Nature 491:342–43 [Google Scholar]
  32. Fullerton SM, Yu JH, Crouch J, Fryer-Edwards K, Burke W. 32.  2010. Population description and its role in the interpretation of genetic association. Hum. Genet. 127:563–72 [Google Scholar]
  33. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S. 33.  et al. 2014. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. . PNAS 111:14205–10 [Google Scholar]
  34. Garcia-Closas M, Gunsoy NB, Chatterjee N. 34.  2014. Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. J. Natl. Cancer Inst. 106:dju305 [Google Scholar]
  35. Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS. 35.  et al. 2013. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res 73:2211–20 [Google Scholar]
  36. Gillman MW, Hammond RA. 36.  2016. Precision treatment and precision prevention: integrating “below and above the skin.”. JAMA Pediatr 170:9–10 [Google Scholar]
  37. Goldenberg AJ, Hull SC, Wilfond BS, Sharp RR. 37.  2011. Patient perspectives on group benefits and harms in genetic research. Public Health Genom 14:135–42 [Google Scholar]
  38. Gordon RS Jr. 38.  1983. An operational classification of disease prevention. Public Health Rep 98:107–9 [Google Scholar]
  39. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR. 39.  et al. 2013. ACMG recommendations for reporting incidental findings in clinical exome and genome sequencing. Genet. Med. 15:565–74 [Google Scholar]
  40. Harrington A. 40.  2012. The fall of the schizophrenogenic mother. Lancet 379:1292–93 [Google Scholar]
  41. Hatzenbuehler ML, Phelan JC, Link BG. 41.  2013. Stigma as a fundamental cause of population health inequalities. Am. J. Public Health 103:813–21 [Google Scholar]
  42. Hedgecoe A. 42.  2004. The Politics of Personalized Medicine: Pharmacogenetics in the Clinic Cambridge, UK: Cambridge Univ. Press
  43. Hens K, Dondorp W, Handyside AH, Harper J, Newson AJ. 43.  et al. 2013. Dynamics and ethics of comprehensive preimplantation genetic testing: a review of the challenges. Hum. Reprod. Update 19:366–75 [Google Scholar]
  44. Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S. 44.  et al. 2016. The impact of communicating genetic risks of disease on risk reducing health behaviour: systematic review with meta-analysis. BMJ 352:i1102 [Google Scholar]
  45. Ingles J, Johnson R, Sarina T, Yeates L, Burns C. 45.  et al. 2015. Social determinants of health in the setting of hypertrophic cardiomyopathy. Int. J. Cardiol. 184:743–49 [Google Scholar]
  46. Juengst ET. 46.  2009. Population genetic research and screening: conceptual and ethical issues. The Oxford Handbook of Bioethics B Steinbock 471–90 New York: Oxford Univ. Press [Google Scholar]
  47. Juengst ET, Fishman JR, McGowan ML, Settersten RA Jr. 47.  2014. Serving epigenetics before its time. Trends Genet 30:427–29 [Google Scholar]
  48. Juengst ET, McGowan ML, Fishman JR, Settersten RA Jr. 48.  2016. From “personalized” to “precision” medicine: the ethical and social implications of rhetorical reform in genomic medicine. Hastings Cent. Rep. 46:21–33 [Google Scholar]
  49. Kahn J. 49.  2004. How a drug becomes “ethnic”: law, commerce, and the production of racial categories in medicine. Yale J. Health Policy Law Ethics 4:1–46 [Google Scholar]
  50. Kahn J. 50.  2012. Race in a Bottle: The Story of BiDil and Racialized Medicine in a Post-Genomic Age New York: Columbia Univ. Press
  51. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C. 51.  et al. 2017. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet. Med. 19:249–55 [Google Scholar]
  52. Kaye C, Laxova R, Livingston JE, Lloyd-Puryear MA, Mann M. 52.  et al. 2001. Integrating genetic services into public health: guidance for state and territorial programs. Community Genet 4:175–96 [Google Scholar]
  53. Kennedy SR, Loeb LA, Herr AJ. 53.  2012. Somatic mutations in aging, cancer and neurodegeneration. Mech. Ageing Dev. 133:118–26 [Google Scholar]
  54. Khoury MJ. 54.  2015. The success of precision medicine requires a public health perspective. Genomics and Health Impact Blog Jan. 29. https://blogs.cdc.gov/genomics/2015/01/29/precision-medicine
  55. Khoury MJ. 55.  2016. Precision public health: more precision ahead for individual and population interventions. Genomics and Health Impact Blog Sept. 7. https://blogs.cdc.gov/genomics/2016/09/07/precision_public_health
  56. Khoury MJ, Bowen MS, Burke W, Coates RJ, Dowling NF. 56.  et al. 2011. Current priorities for public health practice in addressing the role of human genomics in improving population health. Am. J. Prev. Med. 40:486–93 [Google Scholar]
  57. Khoury MJ, Evans JP. 57.  2015. A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefit. JAMA 313:2117–18 [Google Scholar]
  58. Khoury MJ, Gwinn M, Burke W, Bowen S, Zimmern R. 58.  2007. Will genomics widen or help heal the schism between medicine and public health?. Am. J. Prev. Med. 33:310–17 [Google Scholar]
  59. Khoury MJ, Gwinn M, Glasgow RE, Kramer BS. 59.  2012. A population perspective on how personalized medicine can improve health. Am. J. Prev. Med. 42:639–45 [Google Scholar]
  60. King MC, Levy-Lahad E, Lahad A. 60.  2014. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 312:1091–2 [Google Scholar]
  61. Kleiner YS. 61.  2010. Racial profiling in the name of national security: protecting minority travelers’ civil liberties in the age of terrorism. Boston Coll. Third World Law J. 30:103–44 [Google Scholar]
  62. Koenig BA, Lee SS, Richardson SS. 62.  2008. Revisiting Race in a Genomic Age New Brunswick, NJ: Rutgers Univ. Press
  63. Kuehn BM. 63.  2013. After 50 years, newborn screening continues to yield public health gains. JAMA 309:1215–17 [Google Scholar]
  64. Kuszler PC. 64.  2011. The social, political, and economic underpinnings of biomedical research and development: a formidable status quo. Achieving Justice in Genomic Translation: Rethinking the Pathway to Benefit W Burke, K Edwards, S Goering, S Holland, SB Trinidad 22–39 New York: Oxford Univ. Press [Google Scholar]
  65. Lázaro-Muñoz G, Conley JM, Davis AM, Van Riper M, Walker RL, Juengst ET. 65.  2015. Looking for trouble: preventive genomic sequencing in the general population and the role of patient choice. Am. J. Bioeth. 15:3–14 [Google Scholar]
  66. Lee SS. 66.  2009. Defining statistical race and phenotypic race and their implications for health disparities. Curr. Pharmacogenom. Pers. Med. 7:238–42 [Google Scholar]
  67. Lemke T. 67.  2001. ‘The birth of bio-politics’: Michel Foucault's lecture at the Collège de France on neo-liberal governmentality. Econ. Soc. 30:190–207 [Google Scholar]
  68. Loi M, Del Savio L, Stupka E. 68.  2013. Social epigenetics and equality of opportunity. Public Health Ethics 6:142–53 [Google Scholar]
  69. Long EF, Ganz PA. 69.  2015. Cost-effectiveness of universal BRCA1/2 screening: evidence-based decision making. JAMA Oncol 1:1217–18 [Google Scholar]
  70. Lupkin S, Findlay S. 70.  2016. Winners and losers with the 21st Century Cures bill. Shots: Health News from NPR Dec. 2. http://www.npr.org/sections/health-shots/2016/12/02/504139105/winners-and-losers-if-21st-century-cures-bill-becomes-law
  71. Manrai AK, Funke BH, Rehm HL, Olesen MS, Maron BA. 71.  et al. 2016. Genetic misdiagnoses and the potential for health disparities. N. Engl. J. Med. 375:655–65 [Google Scholar]
  72. McCarthy JP. 72.  2011. Toxic matters: protecting our families from toxic substances Broch., Univ. Calif San Francisco: http://www.prhe.ucsf.edu/prhe/pdfs/ToxicMatters.pdf
  73. McEwen JE, Boyer JT, Sun KY. 73.  2013. Evolving approaches to the ethical management of genomic data. Trends Genet 29:375–82 [Google Scholar]
  74. McGowan ML, Cho D, Sharp RR. 74.  2013. The changing landscape of carrier screening: expanding technology and options?. Health Matrix Clevel 23:15–33 [Google Scholar]
  75. McGowan ML, Fishman JR, Settersten RA Jr., Lambrix MA, Juengst ET. 75.  2014. Gatekeepers or intermediaries? The role of clinicians in commercial genomic testing. PLOS ONE 9:e108484 [Google Scholar]
  76. McGowan ML, Settersten RA Jr., Juengst ET, Fishman JR. 76.  2014. Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine. Urol. Oncol. 32:187–92 [Google Scholar]
  77. McGuire AL, McCullough LB, Evans JP. 77.  2013. The indispensable role of professional judgment in genomic medicine. JAMA 309:1465–66 [Google Scholar]
  78. McKie J, Richardson J. 78.  2003. The rule of rescue. Soc. Sci. Med. 56:2407–19 [Google Scholar]
  79. 79. Natl. Inst. Health. 2016. NIH funds precision medicine research with a focus on health disparities News Release, July 28, Natl. Inst. Health, Bethesda, MD. https://www.nih.gov/news-events/news-releases/nih-funds-precision-medicine-research-focus-health-disparities
  80. 80. Natl. Inst. Health. 2016. PMI Cohort Program announces new name: the All of Us Research Program https://www.nih.gov/AllofUs-research-program/pmi-cohort-program-announces-new-name-044all-us-research-program
  81. 81. Natl. Res. Counc. 1975. Genetic Screening: Programs, Principles, and Research Washington, DC: Natl. Acad. Sci.
  82. 82. Natl. Res. Counc. 2011. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease Washington, DC: Natl. Acad. Press
  83. 83. Natl. Res. Counc., Inst. Med. 2009. Preventing Mental, Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities Washington, DC: Natl. Acad. Press
  84. Noar SM, Benac CN, Harris MS. 84.  2007. Does tailoring matter? Meta-analytic review of tailored print health behavior change interventions. Psychol. Bull. 133:673–93 [Google Scholar]
  85. Parens E, Asch A. 85.  2000. Prenatal Testing and Disability Rights Washington, DC: Georgetown Univ. Press
  86. Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H. 86.  et al. 2011. Polygenic susceptibility to prostate and breast cancer: implications for personalized screening. Br. J. Cancer 104:1656–63 [Google Scholar]
  87. Phelan JC, Link BG, Tehranifar P. 87.  2010. Social conditions as fundamental causes of health inequalities: theory, evidence, and policy implications. J. Health Soc. Behav. 51:S28–40 [Google Scholar]
  88. Piel FB, Tatem AJ, Huang Z, Gupta S, Williams TN. 88.  et al. 2014. Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000. Lancet Glob. Health. 2:e80–89 [Google Scholar]
  89. Popejoy AB, Fullerton SM. 89.  2016. Genomics is failing on diversity. Nature 538:161–64 [Google Scholar]
  90. 90. Precis. Med. Work. Group. 2015. The Precision Medicine Initiative Cohort Program—building a research foundation for 21st century medicine Rep., Natl. Inst. Health Bethesda, MD:
  91. Prince AE. 91.  2015. Prevention for those who can pay: insurance reimbursement of genetic-based preventive interventions in the liminal state between health and disease. J. Law Biosci. 2:365–95 [Google Scholar]
  92. Ravitsky V, Rousseau F, Laberge AM. 92.  2017. Providing unrestricted access to prenatal testing does not translate to enhanced autonomy. Am. J. Bioeth. 17:39–41 [Google Scholar]
  93. Reardon J. 93.  2005. Race to the Finish: Identity and Governance in the Age of Genomics Princeton, NJ: Princeton Univ. Press
  94. Reilly P. 94.  1999. The Surgical Solution: A History of Involuntary Sterilization in the U.S Baltimore, MD: Johns Hopkins Univ. Press
  95. Rhodes R. 95.  2008. In defense of the duty to participate in biomedical research. Am. J. Bioeth. 8:37–38 [Google Scholar]
  96. Richardson SS, Daniels CR, Gillman MW, Golden J, Kukla R. 96.  et al. 2014. Don't blame the mothers. Nature 512:131–32 [Google Scholar]
  97. Roberts JS, Dolinoy DC, Tarini BA. 97.  2014. Emerging issues in public health genomics. Annu. Rev. Genom. Hum. Genet. 15:461–80 [Google Scholar]
  98. Roberts MJ, Reich MR. 98.  2002. Ethical analysis in public health. Lancet 359:1055–59 [Google Scholar]
  99. Rose N. 99.  1999. Powers of Freedom: Reframing Political Thought Cambridge, UK: Cambridge Univ. Press
  100. Rothstein M, Epps P. 100.  2001. Science and society: ethical and legal implications of pharmacogenomics. Nat. Rev. Genet. 2:228–31 [Google Scholar]
  101. Rotimi CN. 101.  2012. Health disparities in the genomic era: the case for diversifying ethnic representation. Genome Med 4:65 [Google Scholar]
  102. Sankar PL, Cho MK, Condit CM, Hunt LM, Koenig B. 102.  et al. 2007. Genetic research and health disparities. JAMA 291:2985–99 [Google Scholar]
  103. Sankar PL, Parker LS. 103.  2017. The Precision Medicine Initiative's All of Us Research Program: an agenda for research on its ethical, legal, and social issues. Genet. Med. 19:743–50 [Google Scholar]
  104. Sheikh N, Papadakis M, Panoulas VF, Prakash K, Millar L. 104.  et al. 2016. Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the UK. Heart 102:1797–804 [Google Scholar]
  105. Smart A, Martin P, Parker M. 105.  2004. Tailored medicine: Whom will it fit? The ethics of patient and disease stratification. Bioethics 18:322–43 [Google Scholar]
  106. Suter SM. 106.  2002. The routinization of prenatal testing. Am. J. Law Med. 28:233–70 [Google Scholar]
  107. Tarini BA, Christakis DA, Welch HG. 107.  2006. State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results. Pediatrics 118:448–56 [Google Scholar]
  108. Tarini BA, Goldenberg AJ. 108.  2012. Ethical issues with newborn screening in the genomics era. Annu. Rev. Genom. Hum. Genet. 13:381–89 [Google Scholar]
  109. Taruscio D, Mantovani A, Carbone P, Barisic I, Bianchi F. 109.  et al. 2015. Primary prevention of congenital anomalies: recommendable, feasible and achievable. Public Health Genom 18:184–91 [Google Scholar]
  110. Timmermans S, Buchbinder M. 110.  2015. Saving Babies? The Consequences of Newborn Genetic Screening Chicago: Univ. Chicago Press
  111. Wailoo K, Nelson A, Catherine Lee C. 111.  2012. Genetics and the Unsettled Past: The Collision of DNA, Race, and History New Brunswick, NJ: Rutgers Univ. Press
  112. Williams DR, Costa MV, Odunlami AO, Mohammed SA. 112.  2008. Moving upstream: how interventions that address the social determinants of health can improve health and reduce disparities. J. Public Health Manag. Pract. 14:Suppl.S8–17 [Google Scholar]
  113. Wilson JMG, Jungner F. 113.  1968. Principles and Practice of Screening for Disease Public Health Pap. 34 Geneva: World Health Organ.
  114. Winston FK, Puzino K, Romer D. 114.  2016. Precision prevention: time to move beyond universal interventions. Inj. Prev. 22:87–91 [Google Scholar]
  115. Wolpe PR. 115.  1998. The triumph of autonomy in American medical ethics: a sociological view. Bioethics and Society: Sociological Investigations of the Enterprise of Bioethics R DeVries, J Subedi 38–59 New York: Prentice Hall [Google Scholar]
  116. Yudell M, Roberts D, DeSalle R, Tishkoff S. 116.  2016. Taking race out of human genetics. Science 351:564–65 [Google Scholar]
/content/journals/10.1146/annurev-genom-091416-035222
Loading
  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error